Evidence map›Paper›PMID 37875924›Full record

ArticleJournal of translational medicine2023

One episode of low intensity aerobic exercise prior to systemic AAV9 administration augments transgene delivery to the heart and skeletal muscle.

Christina A Pacak, Silveli Suzuki-Hatano, Fatemeh Khadir, Audrey L Daugherty, Mughil Sriramvenugopal, Bennett J Gosiker, Peter B Kang, William Todd Cade

Abstract read
In one paragraph

Article in Journal of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. What can ATP content tell us about Barth syndrome muscle phenotypes?Journal of translational genetics and genomics · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Christina A PacakPaul and Sheila Wellstone Muscular Dystrophy Center and Department of Neurology, University of Minnesota Medical School, 420 Delaware St SE, Minneapolis, MN, 55455, USA. cpacak@umn.edu.ORCID http://orcid.org/0000-0002-7430-124X
Silveli Suzuki-HatanoCollege of Medicine, Department of Pediatrics, University of Florida, Gainesville, USA.
Fatemeh KhadirPaul and Sheila Wellstone Muscular Dystrophy Center and Department of Neurology, University of Minnesota Medical School, 420 Delaware St SE, Minneapolis, MN, 55455, USA.
Audrey L DaughertyPaul and Sheila Wellstone Muscular Dystrophy Center and Department of Neurology, University of Minnesota Medical School, 420 Delaware St SE, Minneapolis, MN, 55455, USA.
Mughil SriramvenugopalCollege of Medicine, Department of Pediatrics, University of Florida, Gainesville, USA.
Bennett J GosikerCollege of Medicine, Department of Pediatrics, University of Florida, Gainesville, USA.
Peter B KangPaul and Sheila Wellstone Muscular Dystrophy Center and Department of Neurology, University of Minnesota Medical School, 420 Delaware St SE, Minneapolis, MN, 55455, USA.
William Todd CadePhysical Therapy Division, Department of Orthopaedic Surgery, Duke University School of Medicine, 311 Trent Drive, Durham, NC, 27710, USA. todd.cade@duke.edu.

Funding

Heart and Skeletal Muscle Metabolism, Energetics and Function in Barth SyndromeR01HL107406 · NHLBI · WASHINGTON UNIVERSITY · PI CADE, WILLIAM TODD · 2012 to 2016
$2.2M
Mechanisms and Treatment of Cardiac and Skeletal Muscular Dysfunction in Barth SyndromeR01HL136759 · NHLBI · UNIVERSITY OF MINNESOTA · PI PACAK, CHRISTINA A. · 2018 to 2022
$2.2M
NHLBI NIH HHS R01 HL107406NIH HHS R01 HL107406-01A1NIH HHS R01 HL136759-01A1
6 · The paper itself

Abstract

introductionThe promising potential of adeno-associated virus (AAV) gene delivery strategies to treat genetic disorders continues to grow with an additional three AAV-based therapies recently approved by the Food and Drug Administration and dozens of others currently under evaluation in clinical trials. With these developments, it has become increasingly apparent that the high doses currently needed for efficacy carry risks of toxicity and entail enormous manufacturing costs, especially for clinical grade products. Strategies to increase the therapeutic efficacy of AAV-mediated gene delivery and reduce the minimal effective dose would have a substantial impact on this field. We hypothesized that an exercise-induced redistribution of tissue perfusion in the body to favor specific target organs via acute aerobic exercise prior to systemic intravenous (IV) AAV administration could increase efficacy.

backgroundAerobic exercise triggers an array of downstream physiological effects including increased perfusion of heart and skeletal muscle, which we expected could enhance AAV transduction. Prior preclinical studies have shown promising results for a gene therapy approach to treat Barth syndrome (BTHS), a rare monogenic cardioskeletal myopathy, and clinical studies have shown the benefit of low intensity exercise in these patients, making this a suitable disease in which to test the ability of aerobic exercise to enhance AAV transduction.

methodsWild-type (WT) and BTHS mice were either systemically administered AAV9 or completed one episode of low intensity treadmill exercise immediately prior to systemic administration of AAV9.

resultsWe demonstrate that a single episode of acute low intensity aerobic exercise immediately prior to IV AAV9 administration improves marker transgene delivery in WT mice as compared to mice injected without the exercise pre-treatment. In BTHS mice, prior exercise improved transgene delivery and additionally increased improvement in mitochondrial gene transcription levels and mitochondrial function in the heart and gastrocnemius muscles as compared to mice treated without exercise.

conclusionsOur findings suggest that one episode of acute low intensity aerobic exercise improves AAV9 transduction of heart and skeletal muscle. This low-risk, cost effective intervention could be implemented in clinical trials of individuals with inherited cardioskeletal disease as a potential means of improving patient safety for human gene therapy.

Indexed as

Gene Transfer TechniquesMuscle, SkeletalAnimalsDependovirusGenetic TherapyGenetic VectorsHeartHumansMiceTransgenesAAVAAV9Adeno-associated virusAerobic exerciseBarth syndromeCardioskeletal myopathyGene therapySystemic gene deliveryTAFAZZIN

Identifiers

PMID37875924
PMCPMC10598899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.